Profund Advisors LLC Has $1.64 Million Position in Soleno Therapeutics, Inc. $SLNO

Posted by on May 21st, 2026

Profund Advisors LLC lifted its holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) by 78.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 35,371 shares of the company’s stock after purchasing an additional 15,532 shares during the period. Profund Advisors LLC’s holdings in Soleno Therapeutics were worth $1,638,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in Soleno Therapeutics in the 2nd quarter valued at approximately $25,000. Danske Bank A S bought a new stake in shares of Soleno Therapeutics in the third quarter valued at approximately $27,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Soleno Therapeutics in the third quarter valued at approximately $37,000. Quarry LP acquired a new stake in shares of Soleno Therapeutics in the third quarter worth $47,000. Finally, Osaic Holdings Inc. increased its position in Soleno Therapeutics by 97.7% during the second quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock worth $72,000 after acquiring an additional 423 shares during the period. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics Stock Performance

SLNO stock opened at $53.01 on Thursday. The company has a quick ratio of 5.32, a current ratio of 5.62 and a debt-to-equity ratio of 0.10. Soleno Therapeutics, Inc. has a twelve month low of $29.43 and a twelve month high of $90.32. The company has a market cap of $2.76 billion, a P/E ratio of 29.95 and a beta of -2.22. The business has a fifty day moving average of $45.79 and a 200-day moving average of $45.46.

Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to analyst estimates of $88.55 million. Soleno Therapeutics had a return on equity of 22.85% and a net margin of 33.70%. As a group, equities research analysts expect that Soleno Therapeutics, Inc. will post 3.67 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Piper Sandler cut Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 7th. Zacks Research cut shares of Soleno Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Lifesci Capital cut shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Finally, HC Wainwright downgraded shares of Soleno Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the stock from $100.00 to $53.00 in a research report on Wednesday, April 8th. Three equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Soleno Therapeutics currently has an average rating of “Hold” and a consensus price target of $76.67.

View Our Latest Report on SLNO

Soleno Therapeutics Profile

(Free Report)

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.

Featured Stories

Want to see what other hedge funds are holding SLNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report).

Institutional Ownership by Quarter for Soleno Therapeutics (NASDAQ:SLNO)

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.